Publications by authors named "Linzhang Zhang"

Article Synopsis
  • Cholestatic liver diseases (CLD) happen when the liver has trouble making and getting rid of bile, and often the only cure is a liver transplant.
  • Isoastragaloside I (IAS I), found in the Astragalus plant, can help with CLD, but scientists don’t completely understand how it works yet.
  • This study tested how IAS I affects mice with CLD by looking at their blood, liver health, and other important markers, finding that IAS I improved their condition significantly.
View Article and Find Full Text PDF

Total astragalus saponins (TAS) are the main active components of astragali radix, and have potent anti-hepatic fibrosis effect. However, the therapeutic efficacy of TAS and their potential mechanisms in the treatment of primary sclerosing cholangitis (PSC) remain unclear. In this study, two mouse models of PSC, including 3,5-Diethoxycarbonyl-1,4-Dihydro-2,4,6-Collidine (DDC)-induced PSC and Mdr2 spontaneous PSC, and the Tgr5 mice were used to investigate the therapeutic effect and mechanisms of TAS.

View Article and Find Full Text PDF

Ophiopogonis Radix is a well-known Traditional Chinese Medicine and functional food that is rich in polysaccharides and has fructan as a characteristic component. In this study, an inulin neoseries-type fructan designated as OJP-W2 was obtained and characterized from Ophiopogonis Radix, and its potential therapeutic effect on liver fibrosis in vivo were investigated. Structural studies revealed that OJP-W2 had a molecular weight of 5.

View Article and Find Full Text PDF

Renal fibrosis (RF) is a common pathological feature of chronic kidney disease (CKD), which remains a major public health problem. As now, there is still lack of chemical or biological drugs to reverse RF. Shen-shuai-yi Recipe (SSYR) is a classical Chinese herbal formula for the treatment of CKD.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Cholestatic Liver Fibrosis (CLF) is a hepatobiliary disease that typically arises as a late-stage complication of cholestasis, which can have multiple underlying causes. There are no satisfactory chemical or biological drugs for CLF. Total Astragalus saponins (TAS) are considered to be the main active constituents of the traditional Chinese herb Astragali Radix (AR), which has the obvious improvement effects for treating CLF.

View Article and Find Full Text PDF

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease characterized by inflammation and hepatic steatosis that may coincide with fibrotic activity. To date, no pharmacological agents have been approved for NASH treatment. Here, a homogeneous (1,3),(1,6)-β-D-glucan (PUP-W-1, Mw: 41.

View Article and Find Full Text PDF

Ductular reaction (DR) is a common pathological change and thought to have a key role in the pathogenesis and progression of liver fibrosis. Our previous study reported Gypenosides (GPs) ameliorated liver fibrosis, however, the anti-fibrotic mechanisms of GPs are still unclear. Liver fibrosis was induced in rats by carbon tetrachloride combining with 2-acerylaminofluorene (CCl/2-AAF), and Mdr2 knockout ( ) mice to evaluate the anti-fibrotic role of GPs.

View Article and Find Full Text PDF

Cholestatic liver disease (CLD) is a chronic liver disease characterized by ductular reaction, inflammation and fibrosis. As there are no effective chemical or biological drugs now, majority of CLD patients eventually require liver transplantation. Astragali radix (AR) is commonly used in the clinical treatment of cholestatic liver disease and its related liver fibrosis in traditional Chinese medicine, however its specific active constituents are not clear.

View Article and Find Full Text PDF

Liver fibrosis is a common pathological process of all chronic liver diseases. Hepatic stellate cells (HSCs) play a central role in the development of liver fibrosis. Cyclin-dependent kinase 9 (CDK9) is a cell cycle kinase that regulates mRNA transcription and elongation.

View Article and Find Full Text PDF
Article Synopsis
  • Amygdalin (Amy) shows potential as a treatment for anti-hepatic fibrosis, but its pharmacokinetics and comparison with its metabolite prunasin (Pru) haven't been thoroughly investigated.
  • The study aimed to examine the pharmacokinetic properties and anti-fibrotic effects of both substances in live subjects and lab settings, while also determining if Amy is converted to Pru in the body.
  • Results indicated good reliability for measuring Amy and Pru in rat plasma, highlighting significant differences in their pharmacokinetic profiles, and showed that both have beneficial effects against liver fibrosis in mice models.
View Article and Find Full Text PDF

Background: Liver fibrosis is a dysregulated wound-healing process in response to diverse liver injuries, and an effective drug therapy is not yet available. Genistein, which is one of the most active natural flavonoids mainly derived from soybean products (e.g.

View Article and Find Full Text PDF